Drug intelligence / Profile preview

PES-Cl

Development stage
Preclinical
Lead developer
The Wistar Institute
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

PES-Cl is a small molecule inhibitor of the heat shock protein 70 (HSP70) and a potent inhibitor of autophagy. It is a chlorinated analogue of phenylethynesulfonamide (PES) with significantly enhanced potency (approximately 10-fold lower IC50) and improved ability to inhibit autophagy compared to its parent compound. PES-Cl binds specifically to the C-terminal helical 'lid' domain of HSP70, which is abundantly expressed in tumor cells and stabilizes lysosomal membranes. By inhibiting HSP70, PES-Cl disrupts the function of the HSP70/HSC70 co-chaperone system, leading to the degradation of HSP90 client proteins such as HER2, AKT, and CDK4. Additionally, it has been shown to impair the activity of the Anaphase Promoting Complex/Cyclosome (APC/C), inducing G2/M cell cycle arrest. In preclinical studies, PES-Cl demonstrated efficacy against melanoma (including BRAF-inhibitor resistant strains) and B-cell lymphoma with minimal toxicity to normal cells.

02

Targets

DnaK (Mycobacterial DnaK)APC/C–CDC20 (Anaphase-promoting complex/cyclosome–CDC20 complex)

Beyond the preview

Go deeper on PES-Cl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PES-Cl.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call